tiprankstipranks
Advertisement
Advertisement

ACXP Stock Latest News

Acurx announces $7.1M registered direct offering priced at-the-market
The FlyAcurx announces $7.1M registered direct offering priced at-the-market
7d ago
ACXP
Acurx Pharmaceuticals Secures New Financing to Advance Pipeline
PremiumCompany Announcements
Acurx Pharmaceuticals Secures New Financing to Advance Pipeline
7d ago
8K
ACXP
New to The Street announce re-signing of Acurx Pharmaceuticals
PremiumThe Fly
New to The Street announce re-signing of Acurx Pharmaceuticals
16d ago
ACXP
Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors
PremiumThe Fly
Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors
24d ago
ACXP
Acurx price target lowered to $10 from $20 at Alliance Global
PremiumThe Fly
Acurx price target lowered to $10 from $20 at Alliance Global
1M ago
ACXP
Acurx reports Q4 EPS (73c) vs. ($3.29) last year
PremiumThe FlyAcurx reports Q4 EPS (73c) vs. ($3.29) last year
1M ago
ACXP
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
Premium
Market News
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
1M ago
ACXP
ACXP Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ACXP Earnings this Week: How Will it Perform?
1M ago
ACXP
Acurx Advances Ibezapolstat Program for Recurrent C. difficile
PremiumCompany Announcements
Acurx Advances Ibezapolstat Program for Recurrent C. difficile
2M ago
8K
ACXP
Acurx announces new ibezapolstat clinical trial program
PremiumThe Fly
Acurx announces new ibezapolstat clinical trial program
2M ago
ACXP
Acurx files to sell 750,000 shares of common stock for holders
PremiumThe Fly
Acurx files to sell 750,000 shares of common stock for holders
3M ago
ACXP
Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO
PremiumThe Fly
Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO
3M ago
ACXP
One new option listing and option delistings on January 20th
PremiumThe FlyOne new option listing and option delistings on January 20th
3M ago
CVM
TEF
Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation
Premium
Ratings
Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation
5M ago
ACXP
Acurx Pharmaceuticals Reports Q3 2025 Financial Results
Premium
Company Announcements
Acurx Pharmaceuticals Reports Q3 2025 Financial Results
5M ago
ACXP
Acurx Pharmaceuticals’ Earnings Call: Achievements Amid Challenges
PremiumCompany Announcements
Acurx Pharmaceuticals’ Earnings Call: Achievements Amid Challenges
5M ago
ACXP
Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength
PremiumRatings
Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength
5M ago
ACXP
Acurx reports Q3 EPS ($1.23) vs. ($3.45) last year
PremiumThe Fly
Acurx reports Q3 EPS ($1.23) vs. ($3.45) last year
5M ago
ACXP
Acurx announces publication of results from ibezapolstat study
PremiumThe Fly
Acurx announces publication of results from ibezapolstat study
5M ago
ACXP
Is ACXP a Buy, Before Earnings?
PremiumPre-EarningsIs ACXP a Buy, Before Earnings?
5M ago
ACXP
Acurx Pharmaceuticals’ Ibezapolstat: Promising Preclinical and Clinical Efficacy Supports Buy Rating
Premium
Ratings
Acurx Pharmaceuticals’ Ibezapolstat: Promising Preclinical and Clinical Efficacy Supports Buy Rating
6M ago
ACXP
Acurx files to sell 585,000 shares of common stock for holders
Premium
The Fly
Acurx files to sell 585,000 shares of common stock for holders
6M ago
ACXP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >